Photocure Regains Rights to Cysview in Canada Further Consolidating its Bladder Cancer Franchise
Press release – Oslo, Norway, 25 August 2021: Photocure ASA (Photocure, PHO: OSE) announces that it has reached agreement with BioSyent Pharma Inc. (“BioSyent”) to reacquire the marketing and distribution rights to Cysview[® ]in Canada. The parties entered into a final agreement today, stipulating that commercial rights will transfer to Photocure on January 1[st], 2022. The reacquisition of marketing and distribution rights enables Photocure’s direct management of the Cysview brand in Canada and consolidates the territory into Photocure’s existing U.S. business to form its North America sales